BTK and B-cell chronic lymphocytic leukemia: Bruton’s tyrosine kinase (BTK) is a component of the B cell receptor (BCR) signalling pathway, which is critical in the maturation of B cells, and as such, BTK has emerged as a therapeutic target for B cell malignancies such as CLL [9].